Clinical relevance of detection of tumor cells in the bone marrow of primary breast cancer patients: A review

Oncology Research and Treatment

Volumn 20, Issue 5, 1997, Pages 387-392

  Harbeck, N ^a   Abdulsalam, A ^a,b   Janicke F ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Department of Obstetrics and Gynecology of the University of Damascus ^*  (Syrian Arab Republic)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone marrow; Breast cancer; Prognosis; Tumor cells

Indexed keywords

BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; HUMAN; IMMUNOCYTOCHEMISTRY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TUMOR CELL;

EID: 0030691210     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218989     Document Type: Article

References (35)

1. Fisher B, Slack NH, Bross IDJ and cooperating investigators: Cancer of the breast: Si/e of tumor and prognosis, Cancer 1969:24:1071-1080.
2. Ridell B, Landys K: Incidence and histopathology of métastasés of mammary carcinoma in biopsies from the posterior iliac crest, Cancer 1979:4:1782-1788.
3. Sloane JP, Ormerod MG, Imrie SF, Coombes RC: The use of antisera to epithelial membrane antigen in detecting micromelastases in histological sections, Br J Cancer 1980:42:392-398.
4. Dcarnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HMD, Powles TJ, Ford HT, Gazet JP, Neville AM: Increased detection of mammary carcinoma cells in marrow smears using anti-sera to epithelial membrane antigen, Br J Cancer 1981:44:85-90.
5. Redding WH, Monaghan P, Imrie S, Ormerod M, Gazet JC, Clink HMD, Dcarnaley DP: Detection of micrometastases in patients with primary breast cancer, Lancet 1983:3:1271-1274.
6. Jauch KW, Friess S, Griitzner U, Heiss MM, Funke I: Prognostic significance of micrometastases Onkologie 1995:18:525-532.
7. Heyderman E, McCartney JC: Epithelial membrane antigen and lymphoid cells, Lancet 1985:1:109.
8. Schlimok G, Funke I, Holzmann B, Göttlinger G, Schmidt G, Häuser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer in bone marrow:ln vitro detection with anti-cytokcratin and in vivo labelling with anti-17-1A monoclonal antibodies, Proc Natl Acad Sei 1987:84:8672-8676.
9. Harbeck N, Untch M, Pache L, Eiermann W: Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: results of a three-year median follow-up, Br J Cancer 1994:69:566-571.
10. I Menard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi MI: Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features, Br J Cancer 1994:69:1126-1129.
11. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, Barletta L, Menard S, Colnaghi MI: Use of monoclonal antibody MBrl to detect micrometastases in bone marrow specimens of breast cancer patients, Eur J Cancer 1990:26: 865-867.
12. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis, J Gin Oncol 1992:10: 1534-1539.
13. Osborne MP, Asina S, Wong GY, Old LJ, Cote RJ: Immunofluorescent monoclonal antibody detection uf breast cancer in bone marrow: Sensitivity in a model system, Cancer Res 1989:49:2510-2513.
14. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP: Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow, Cancer Res 1991;51:2706-2709.
15. Coombes RC, Dcarnaley DP, Redding WH, Ormerod MG, Skillon RA, Sloane JP, Imrie S, Edwards AW, Monaghan P, Neville AM: Micrometastases in breast cancer: in Peeters H (ed): Protides of the biological fluids, Oxford, Pergamon, 1983. pp 317-323.
16. Mathieu MC, Friedman S, Bosq J, Cailou B, Spiel-mann M, Travagli JP, Contesso G: Immunohisto-chemical staining of bone marrow biopsie for detection of occult metastasis in breast cancer, Breast Cancer Res Treat 1990:15:21-26.
17. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, Coombes RC: The fate of bone marrow micrometastases in patients with primary breast cancer, J Clin Oncol 1989:7:445-449.
18. Mansi JL, Easton D, Berger U, Gazet JC, Ford II I, Dcarnaley D, Coombes RC: Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up, Eur J Cancer 1991:27:1552-1555.
19. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Holler H, Graeff H: Urokinase (uPA) and its inhibitor (PA1-1) are strong and independent prognostic factors in node-negative breast cancer, Breast Cancer Res Treat 1993:24:195-208.
20. Thomssen C, Oppclt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Graeff H, Schmitt M: Identification of low-risk node-negative breast cancer patients by tumor biological factors PA 1-1 and cathepsin L, Anticancer Res 1997. in press
21. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H, Höfler H: Prognostic impact of the proliferation associated factors Ki-67 and S-phase in node-negative breast cancer using MIB1 immunostaining and flowcytofluorometric S-phase determination, Br J Cancer 1997:75:1525-1533.
22. Merkle E, Bähr J, Henke A, Bühner M, Martus P: Immunzytochemischer Nachweis von Tumorzellen im Knochenmark als Prognosefaktor beim Mammakarzinom, Geburtshilfe Frauenheilkd 1994:54: 662-669.
23. Cotc RJ, Rosen PP, Lesser ML, Old U, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases, J Clin Oncol 199l;9: 1749-1756.
24. riansi JL, Berger U, Easton D, McDonnell I, Eedding II, Gazet JC, McKinna A, Powles T, oombcs RC: Micrometastases in bone marrow in aticnts with primary breast cancer: Evaluation as in early predictor of bone metastases, Br Med J 987:295:1093-1096.
25. jiai M, Natoli C, Sismondi P, Biglia N, Lesti G, riulieri M, Iacobelli S: Bone marrow micromolas-ascs defected by a monoclonal antibody in patients vith breast cancer, Anticancer Res 1990:10:119-122.
26. riolino A, Colombatti M, Bonetti F, Zardini M, Yisini F, Perini A, Pelosi G, Tridente G, Veneri D, retto GL: A comparative analysis of three different echniques for the detection of breast cancer cells in one marrow, Cancer 1991;67:1033-1036.
27. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Vagner C, Neumaier M: Specific detection of carci-ìoembryonic antigen-expressing tumor cells in bone narrow aspirates by polymerase chain reaction, J Z\in Oncol 1994:12:725-729.
28. Datta YH, Adams PT, Drobyski WR, Ethier SP, rcrry VH, Roth MS: Sensitive detection of occult breast cancer by reverse-transkriptase polymerase :hain reaction, J Clin Oncol 1994:12:475-482.
29. Panici K, Riethmüller G: Methods for detection of nicrometastatic carcinoma cells in bone marrow, iilood and lymph nodes, Onkologie 1995:18: 394-401.
30. Kunke I, Fries S, Jauch KW: Tumorzcllnachweis im Knochenmark: Entscheidungshilfe zur adjuvanten Therapie bei nodal-negativen Patientinnen mit Mammakarzinom, Chirurg 1991:62:805-809.
31. McGuire W: Breast cancer prognostic factors: Evaluation guidelines, J Natl Cancer Inst 1991:83: 154-155.
32. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Precht! A, Ulm K, Jänicke F, Höfler H, Graeff II, Schmitt M: Prognostic impact of tumor biological factors on survival in node-negative breast cancer, Anticancer Res 1997: in press
33. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW: Tumor associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase type plasminogen activator system, J Clin Oncol 1995:13:2084-2093.
34. Schlimok G, Riethmüller G: Monoclonal antibodies in the therapy of minimally residual solid tumors, Onkologie 1995:18:403-408.
35. Graeff H, Wilhelm O, Jänicke F, Schmitt M: Tumor-biologie-orientierte Behandlungskonzepte, Gynakol Geburtshilfliche Rundsch 1993:33 (suppl 1):193-196